Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window
Voyager Therapeutics shares rose 4 cents to $3.83 in thin premarket trading, valuing the company at $228 million. H.C. Wainwright reiterated a Buy rating and $25 target, citing upcoming milestones including first human dosing for VY1706 and tau PET imaging data for VY7523 in the second half of 2026. Voyager reported $171.7 million in cash at the end of Q1.